<?xml version="1.0" encoding="UTF-8"?>
<xml>
<records>
<record>
  <ref-type name="Journal Article">17</ref-type>
  <contributors>
    <authors>
      <author>Tschirner, Sarah K</author>
      <author>Schmidt, Andree</author>
      <author>Ito, Mana</author>
      <author>Hyakkoku, Kana</author>
      <author>Yoshimura, Akimasa</author>
      <author>Müller, Stephan A</author>
      <author>Horiguchi, Naotaka</author>
      <author>Lichtenthaler, Stefan F</author>
    </authors>
    <subsidiary-authors>
      <author>AG Lichtenthaler</author>
    </subsidiary-authors>
  </contributors>
  <titles>
    <title>Elenbecestat and Compound 89 Potently Inhibit BACE1 but Not BACE2 When Subchronically Dosed in Non-Human Primates.</title>
    <secondary-title>Proteomics</secondary-title>
  </titles>
  <periodical>
    <full-title>Proteomics</full-title>
  </periodical>
  <publisher>Wiley VCH</publisher>
  <pub-location>Weinheim</pub-location>
  <isbn>1615-9853</isbn>
  <electronic-resource-num>10.1002/pmic.70082</electronic-resource-num>
  <language>English</language>
  <pages>100 - 107</pages>
  <number>1</number>
  <volume>26</volume>
  <abstract>The β-secretase BACE1 (β-site amyloid precursor (APP) cleaving enzyme 1) is a major drug target for Alzheimer's disease (AD), as it catalyzes the first step in amyloid β (Aβ) generation, but has additional substrates and functions, in particular in the brain. Several advanced clinical trials with BACE1 inhibitors were stopped because of an adverse event, a mild cognitive worsening. The underlying mechanism is not yet known but may result from co-inhibition of the BACE1-homolog BACE2. While a cerebrospinal fluid (CSF) biomarker for measuring BACE2 activity is not yet established, VCAM-1 has been suggested as such a biomarker, but has not yet been tested upon prolonged dosing in vivo. Using CSF pharmacoproteomics and a subchronic dosing paradigm in non-human primates, we demonstrate that compound 89, a BACE inhibitor not yet tested in humans, and the clinically tested drug elenbecestat inhibit BACE1 in vivo, with little or no effect on BACE2, as seen with a reduction of substrates of BACE1, but not of the BACE2 substrate VCAM-1. As a control, verubecestat, which inhibits both BACE2 and BACE1, reduced CSF abundance of BACE1 substrates as well as of VCAM-1. This study demonstrates the suitability of VCAM-1 as a pharmacodynamic biomarker for measuring BACE2 target engagement in CSF.</abstract>
  <notes/>
  <label>PUB:(DE-HGF)16, ; 0, ; </label>
  <keywords>
    <keyword>Amyloid Precursor Protein Secretases: antagonists &amp; inhibitors</keyword>
    <keyword>Amyloid Precursor Protein Secretases: cerebrospinal fluid</keyword>
    <keyword>Animals</keyword>
    <keyword>Aspartic Acid Endopeptidases: antagonists &amp; inhibitors</keyword>
    <keyword>Aspartic Acid Endopeptidases: cerebrospinal fluid</keyword>
    <keyword>Male</keyword>
    <keyword>Humans</keyword>
    <keyword>Biomarkers: cerebrospinal fluid</keyword>
    <keyword>Vascular Cell Adhesion Molecule-1: cerebrospinal fluid</keyword>
    <keyword>Macaca fascicularis</keyword>
    <keyword>Amyloid Precursor Protein Secretases</keyword>
    <keyword>Aspartic Acid Endopeptidases</keyword>
    <keyword>BACE1 protein, human</keyword>
    <keyword>Biomarkers</keyword>
    <keyword>Vascular Cell Adhesion Molecule-1</keyword>
  </keywords>
  <accession-num/>
  <work-type>Journal Article</work-type>
  <dates>
    <pub-dates>
      <year>2026</year>
    </pub-dates>
  </dates>
  <accession-num>DZNE-2026-00070</accession-num>
  <year>2026</year>
  <custom2>pmc:PMC12809003</custom2>
  <custom6>pmid:41310967</custom6>
  <urls>
    <related-urls>
      <url>https://pub.dzne.de/record/284027</url>
      <url>https://doi.org/10.1002/pmic.70082</url>
    </related-urls>
  </urls>
</record>

</records>
</xml>